Spectrum Pharma gets 'Hanmi-downs' to boost oncology pipeline
This article was originally published in Scrip
Executive Summary
Spectrum Pharmaceuticals, best known perhaps for its development of the targeted anticancer treatment, Zevalin (ibritumomab tiuxetan), has bolstered its oncology pipeline through the acquisition of selected rights to Hanmi Pharmaceuticals’ long-acting granulocyte colony-stimulating factor product SPI-2012 (HM10460A). Spectrum has indicated that there are signs of improved activity in the novel formulation over conventional versions of the drug.
You may also be interested in...
Spectrum Gears Up To File Rolontis, Stresses Patient Access
Biosimilars of Amgen's blockbuster Neulasta pose a competitive threat to long-acting GSF Rolontis, but the company has experience with group purchasing and notes that large oncology clinics will make more revenue by providing higher-priced products.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.